Serum peptidome profiling for the diagnosis of colorectal cancer: discovery and validation in two independent cohorts
Metrics: PDF 1032 views | HTML 1612 views | ?
Hao Wang1,*, Chenghua Luo2,*, Shengtao Zhu3,4, Honghong Fang1, Qing Gao1, Siqi Ge1,5, Haixia Qu6, Qingwei Ma6, Hongwei Ren7, Youxin Wang1 and Wei Wang1,5
1Beijing Key Laboratory of Clinical Epidemiology, School of Public Health, Capital Medical University, Beijing 100069, China
2Department of Retroperitoneal Tumors Surgery, Peking University International Hospital, Beijing 102206, China
3Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, Beijing 100069, China
4National Center for Clinical Medical Research of Digestive Diseases, Beijing 100069, China
5School of Medical and Health Sciences, Edith Cowan University, Perth 6027, Australia
6Bioyong (Beijing) Technology Co., Ltd., Beijing 100085, China
7School of Life Sciences, Peking University, Beijing 100871, China
*These authors have contributed equally to this work
Wei Wang, email: firstname.lastname@example.org
Youxin Wang, email: email@example.com
Keywords: colorectal cancer, peptidome, MALDI-TOF MS, diagnosis panel
Received: May 18, 2017 Accepted: June 29, 2017 Published: July 26, 2017
Colorectal cancer (CRC) is one of the most common malignant neoplasms worldwide. Except for the existing fecal occult blood test, colonoscopy and sigmoidoscopy, no widely accepted in vitro diagnostic methods have been available. To identify potential peptide biomarkers for CRC, serum samples from a discovery cohort (100 CRC patients and 100 healthy controls) and an independent validation cohort (91 CRC patients and 91 healthy controls) were collected. Peptides were fractionated by weak cation exchange magnetic beads (MB-WCX) and analysed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Five peptides (peaks at m/z 1895.3, 2020.9, 2080.7, 2656.8 and 3238.5) were identified as candidate biomarkers for CRC. A diagnostic panel based on the five peptides can discriminate CRC patients from healthy controls, with an accuracy of 91.8%, sensitivity of 95.6%, and specificity of 87.9% in the validation cohort. Peptide peaks at m/z 1895.3, 2020.9 and 3238.5 were identified as the partial sequences of complement component 4 (C4), complement component 3 (C3) and fibrinogen α chain (FGA), respectively. This study potentiated peptidomic analysis as a promising in vitro diagnostic tool for diagnosis of CRC. The identified peptides suggest the involvement of the C3, C4 and FGA in CRC pathogenesis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.